Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257677 | 0.85 | CYP1A2 (0.37) | CYP1A2 | |
| SCHEMBL6856984 | 0.85 | CYP1A2 (0.37) | CYP1A2 | |
| SCHEMBL2456163 | 0.83 | LMNA (0.33) | — | |
| SCHEMBL2214195 | 0.82 | UGT2B7 (0.35) | — | |
| SCHEMBL2456188 | 0.80 | LMNA (0.31) | — | |
| SCHEMBL6538468 | 0.80 | HTR1B (0.38) | CYP1A2 | |
| SCHEMBL27822818 | 0.79 | MCHR1 (0.40) | — | |
| SCHEMBL64917 | 0.79 | CYP1A2 (0.40) | CYP1A2CYP2A6 | |
| SCHEMBL5227738 | 0.79 | CYP1A2 (0.40) | CYP1A2CYP2A6 | |
| SCHEMBL637304 | 0.78 | HTT (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116703-A1 | 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field | NEUROSEARCH A/S | 2004-06-17 | — | — | US | claimed |
| EP-1133494-B1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH AS (DK) | 2004-02-18 | — | — | EP | claimed |
| US-6680328-B2 | CHOLINERGIC LIGANDS OF NICOTINIC ACETYL CHOLINE RECEPTORS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, SMOOTH MUSCLE CONTRACTION DISORDERS, ENDOCRINE DISEASES/DISORDERS, NEURODEGENERATION, INFLAMMATION, PAIN, AND DRUG WITHDRAWAL | NEUROSEARCH A/S (DK) | 2004-01-20 | — | — | US | claimed |
| US-20020035122-A1 | 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives | ANIONA APS (DK) | 2002-03-21 | — | — | US | claimed |
| EP-1133494-A1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2001-09-19 | — | — | EP | claimed |
| WO-2000032600-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| US-8497334-B2 | Conjugated diene polymer, conjugated diene polymer composition, and method for producing conjugated diene polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-20110245407-A1 | CONJUGATED DIENE POLYMER, CONJUGATED DIENE POLYMER COMPOSITION, AND METHOD FOR PRODUCING CONJUGATED DIENE POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-1797096-B1 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7745446-B2 | Pyrazolo[1,5-c]pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | ALTANA PHARMA AG (DE) | 2007-11-01 | — | — | US | disclosed |
| EP-1797096-A2 | NOVEL PYRAZOLOPYRIMIDINES | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-7045522-B2 | 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field | NEUROSEARCH A/S (DK) | 2006-05-16 | — | — | US | disclosed |
| EP-1133494-A1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2001-09-19 | — | — | EP | disclosed |
| US-6248870-B1 | OLIGO-2,6-PYRIMIDINE COMPLEXING AGENT. | NYCOMED IMAGING AS (NO) | 2001-06-19 | — | — | US | disclosed |
| WO-2000032600-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999039748-A1 | TARGETING IMMUNOREAGENTS USEFUL IN THERAPEUTIC AND DIAGNOSTIC COMPOSITIONS AND METHODS | NYCOMED IMAGING AS (NO) | 1999-08-12 | — | — | WO | disclosed |
| US-5817774-A | Unsymmetrical complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | STERLING WINTHROP INCORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| US-5760191-A | Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | NYCOMED IMAGING AS (NO) | 1998-06-02 | — | — | US | disclosed |
| US-5559214-A | Unsymmetrical complexing agents and targeting immunoreagents useful in thearpeutic and diagnostic compositions and methods | STERLING WINTHROP INC. (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035122-A1 | 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives | CHRNA2, CHRNA7, CHRNA10 | CYP1A2 662/4885CYP2A6 1013/4885 |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | MCL1, RARS2, CDK4 | CYP1A2 1752/4885CYP2A6 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.